Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 9
1990 3
1991 8
1992 11
1993 26
1994 27
1995 29
1996 32
1997 28
1998 17
1999 46
2000 50
2001 49
2002 59
2003 44
2004 43
2005 46
2006 38
2007 33
2008 54
2009 39
2010 51
2011 31
2012 52
2013 38
2014 67
2015 54
2016 69
2017 70
2018 54
2019 71
2020 77
2021 63
2022 58
2023 49
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,396 results

Results by year

Filters applied: . Clear all
Page 1
An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E, Deshpande HA, Stein SM. Guadalupe E, et al. Drugs Today (Barc). 2018 Aug;54(8):457-465. doi: 10.1358/dot.2018.54.8.2834461. Drugs Today (Barc). 2018. PMID: 30209440 Review.
The discovery that the production of this hormone can be inhibited by somatostatin led to the development of somatostatin analogues octreotide and lanreotide, which differ from native somatostatin in that they have a longer half-life. ...This review researches the origins …
The discovery that the production of this hormone can be inhibited by somatostatin led to the development of somatostatin analogues octreoti …
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
The estimated rates of progression-free survival at 24 months were 65.1% (95% CI, 54.0 to 74.1) in the lanreotide group and 33.0% (95% CI, 23.0 to 43.3) in the placebo group. ...The most common treatment-related adverse event was diarrhea (in 26% of the patients in the …
The estimated rates of progression-free survival at 24 months were 65.1% (95% CI, 54.0 to 74.1) in the lanreotide group and 33.0% (95 …
The safety of lanreotide for neuroendocrine tumor.
Godara A, Siddiqui NS, Byrne MM, Saif MW. Godara A, et al. Expert Opin Drug Saf. 2019 Jan;18(1):1-10. doi: 10.1080/14740338.2019.1559294. Epub 2018 Dec 24. Expert Opin Drug Saf. 2019. PMID: 30582380 Review.
As lanreotide is commonly used for management of NET, it is imperative to recognize and appropriately manage any drug-related toxicities. In this review, we will provide an overview of the toxicity with lanreotide and its management. Expert opinion: Lanreotide …
As lanreotide is commonly used for management of NET, it is imperative to recognize and appropriately manage any drug-related toxicit …
Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT. Wolin EM, et al. J Gastrointest Cancer. 2016 Dec;47(4):366-374. doi: 10.1007/s12029-016-9866-9. J Gastrointest Cancer. 2016. PMID: 27619395 Free PMC article. Review.
This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care providers, as well as the most recent clinical evidence demonstrating the safety and efficacy of lanreotide depot in inhibiting tumor g …
This review discusses how the distinct molecule and formulation of lanreotide depot provide advantages to patients and health care pr …
Lanreotide autogel(): a review of its use in the treatment of patients with acromegaly.
Burness CB, Dhillon S, Keam SJ. Burness CB, et al. Drugs. 2014 Sep;74(14):1673-91. doi: 10.1007/s40265-014-0283-8. Drugs. 2014. PMID: 25193626 Review.
Lanreotide Autogel() (ATG) [Somatuline() Autogel(), Somatuline() Depot()] is a prolonged-release, supersaturated aqueous gel formulation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone and ins …
Lanreotide Autogel() (ATG) [Somatuline() Autogel(), Somatuline() Depot()] is a prolonged-release, supersaturated aqueous gel formulat …
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Stueven AK, et al. Int J Mol Sci. 2019 Jun 22;20(12):3049. doi: 10.3390/ijms20123049. Int J Mol Sci. 2019. PMID: 31234481 Free PMC article. Review.
Both the PROMID (placebo-controlled, prospective, randomized study in patients with metastatic neuroendocrine midgut tumors) and the CLARINET (controlled study of lanreotide antiproliferative response in neuroendocrine tumors) trial showed a statistically significant prolo …
Both the PROMID (placebo-controlled, prospective, randomized study in patients with metastatic neuroendocrine midgut tumors) and the CLARINE …
Lanreotide Autogel: a review of its use in the management of acromegaly.
Croxtall JD, Scott LJ. Croxtall JD, et al. Drugs. 2008;68(5):711-23. doi: 10.2165/00003495-200868050-00013. Drugs. 2008. PMID: 18370450 Review.
Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. ...It was …
Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide ace …
Pharmacokinetic evaluation of lanreotide.
Hu M, Tomlinson B. Hu M, et al. Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1301-12. doi: 10.1517/17425255.2010.513700. Expert Opin Drug Metab Toxicol. 2010. PMID: 20716034 Review.
TAKE HOME MESSAGE: Lanreotide is an effective and well-tolerated drug for the treatment of acromegaly. ...In well-designed clinical trials, subcutaneous lanreotide ATG was shown to be no less effective than intramuscular lanreotide SR or octreotide treatment. …
TAKE HOME MESSAGE: Lanreotide is an effective and well-tolerated drug for the treatment of acromegaly. ...In well-designed clinical t …
The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
Cuff H, Lord K, Ballester L, Scully T, Stewart N, De Leon DD. Cuff H, et al. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3115-e3120. doi: 10.1210/clinem/dgac322. J Clin Endocrinol Metab. 2022. PMID: 35587448
OBJECTIVE: To assess the effectiveness and safety of lanreotide in individuals with HI. DESIGN: Retrospective cohort study of individuals with HI treated with lanreotide between 2015 and 2020. ...PATIENTS: Fifty-four individuals with hyperinsulinism treated with …
OBJECTIVE: To assess the effectiveness and safety of lanreotide in individuals with HI. DESIGN: Retrospective cohort study of individ …
Lanreotide for the treatment of acromegaly.
Castinetti F, Saveanu A, Morange I, Brue T. Castinetti F, et al. Adv Ther. 2009 Jun;26(6):600-12. doi: 10.1007/s12325-009-0035-4. Epub 2009 Jun 16. Adv Ther. 2009. PMID: 19533047 Review.
Lanreotide is an eight-amino acid peptide, which is an analog of the native somatostatin peptide, physiological inhibitor of growth hormone (GH). The drug shows high binding affinity for somatostatin receptors, SSTR2 and SSTR5, which is the primary mechanism considered to …
Lanreotide is an eight-amino acid peptide, which is an analog of the native somatostatin peptide, physiological inhibitor of growth h …
1,396 results